Your session is about to expire
← Back to Search
Triple Immunotherapy for Advanced Cancer
Study Summary
This trial will find the best dose of 3 drugs to treat patients with advanced solid tumors. The drugs will be given together and the side effects will be monitored.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any cancer drugs or experimental medications recently.My cancer has spread, and standard treatments or immunotherapy haven't worked or aren't suitable for me.I have an active hepatitis B or C infection.You have been diagnosed with HIV.My side effects from previous treatments are mild or approved by the medical monitor.I have active brain or CNS cancer spread.I have not taken antibiotics or antifungal/antiviral drugs in the last 7 days.My melanoma cannot be surgically removed and didn't respond to previous anti-PD-(L)1 therapy.I have another cancer that is getting worse or needs treatment.I am taking medication to suppress my immune system due to an autoimmune disease.I had side effects from previous immunotherapy.I have melanoma that has not been treated and cannot be surgically removed.I have not received a live vaccine in the last 30 days.My cancer spread to other parts and responded differently to immunotherapy.I have not received colony-stimulating factors in the last 14 days.I have been treated with drugs targeting LAG-3 or TIM-3.I haven't received any cancer treatment recently.I am on long-term steroids.I have had an organ transplant.I am not pregnant or breastfeeding.You have had or currently have a heart test (ECG) that shows a significant problem, according to the doctor.I stopped anti-PD-(L)1 therapy due to side effects and my cancer has worsened.I have a lung condition not caused by an infection.I stopped my anti-PD-(L)1 therapy because it worked as well as it could.I have not had major chest radiation or palliative radiation within the specified times before starting the study treatment.I have or had eye melanoma.I have heart problems that affect my daily activities.I am fully active or can carry out light work.
- Group 1: Phase 2 Cohort B
- Group 2: Phase 1 Part 3
- Group 3: Phase 1 Part 4
- Group 4: Phase 1 Part 1
- Group 5: Phase 1 Part 2
- Group 6: Phase 2 Cohort A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities in North America are currently executing this research?
"This clinical trial has 10 different medical sites that are offering the medication, such as Md Anderson Cancer Center At Cooper in Bethesda, Cancer Center For Blood Disorders in Seattle and University of Washington - Seattle Cancer Care Alliance in New york."
Has there been other research conducted utilizing INCAGN02385?
"At the present moment, there are 26 active clinical trials researching INCAGN02385 with 3 of them in Phase 3. Most studies for this medication are centered around A CORUÑA and Virginia; nonetheless, research is also taking place across 810 other locations worldwide."
Is this research effort still taking on new participants?
"Based on the latest records available online, this clinical trial is now seeking out potential participants. The original posting date of this study was July 27th 2020 and it was recently updated on October 25th 2022."
Is this a pioneering endeavor in clinical research?
"INCAGN02385 has been subject to medical research since 2016, when it was first funded by Incyte Corporation. The Phase 1 drug approval for this medication followed the initial study of 325 patients in that year. Currently, 26 trials are active for INCAGN02385 across 117 cities and 43 nations around the world."
What is the recruitment capacity for this research undertaking?
"Affirmative. Per clinicaltrials.gov, the study initiated on July 27th 2020 and is still open to applicants as of October 25th 2022. 10 sites are seeking a total of 146 participants."
Share this study with friends
Copy Link
Messenger